Aptevo Therapeutics Surges to 66th Most Traded Stock with $96.1 Million Turnover

On June 18, 2025, Aptevo Therapeutics (APVO) experienced a significant surge in trading volume, with a turnover of $96.1 million, marking a 10,852.70% increase from the previous day. This substantial rise in trading activity positioned Aptevo as the 66th most traded stock of the day. The company's stock price also saw a notable increase of 77.66%.

Aptevo Therapeutics recently announced an $8 million offering priced at-the-market under Nasdaq rules. This offering includes 2.47 million shares of common stock or pre-funded warrants and 12.33 million common stock purchase warrants, all priced at $3.25 per share. The company expects to raise approximately $8 million in gross proceeds before deducting placement agent fees, commissions, and offering expenses. This move is part of Aptevo's strategy to secure additional funding for its ongoing research and development efforts in the field of immuno-oncology.

In addition to the recent offering, Aptevo Therapeutics has been actively engaged in various clinical trials and research initiatives. The company's lead candidate, mipletamig, has shown promising results in frontline acute myeloid leukemia (AML) patients, with an 85% remission rate observed in evaluable patients. This drug combination has also enabled a rare pathway to transplant for previously ineligible unfit patients, further highlighting its potential in treating AML. The safety profile of mipletamig remains strong, with no dose-limiting toxicities observed among evaluable patients.

Aptevo Therapeutics has also been focusing on the development of bispecific antibodies, such as APVO711, which combines a checkpoint inhibitor and immune activation. In preclinical studies, APVO711 has demonstrated dual anti-cancer functionality with broad solid tumor potential. This innovation exemplifies the emerging capabilities of Aptevo's proprietary ADAPTIR® platform, which continues to drive the company's research and development efforts in the field of immuno-oncology.